Pixium Vision

https://www.touchophthalmology.com/macular-degeneration/journal-articles/subretinal-photovoltaic-implant-prima-provides-central-vision-in-subjects-with-geographic-atrophy-due-to-age-related-macular-degeneration/

Subretinal Photovoltaic Implant PRIMA Provides Central Vision in Subjects with Geographic Atrophy Due to Age-related Macular Degeneration - touchOPHTHALMOLOGY Age-related macular degeneration (AMD) is one of the main causes of irreversible vision loss in ageing populations worldwide.1 In 2019, the US recorded 1.49

Our CEO Lloyd Diamond will be presenting at LSI - Life Science Intelligence™'s upcoming LSI Europe '23 Emerging Medtech Summit.

Don't miss his talk for a chance to learn more about investing in a late clinical stage bionic vision company with a $1.6bn+ market opportunity.

Time: 10:45-10:54 am (Track 1)
Date: September 19, 2023

👁️ The health repercussions for individuals experiencing severe vision impairment or blindness extend beyond the immediate loss of vision. Not only does not being able to see clearly significantly impact quality of life, but it also brings about several other health-related concerns:

❗️An elevated risk of depression: Without sight, many face challenges in social interactions, mobility, and daily tasks, leading to feelings of isolation and a higher propensity for depressive disorders.
❗️An increased likelihood of early admission to nursing homes and long-term care facilities: Due to the decreased ability to independently manage daily activities and the potential lack of familial or community support, many blind individuals find themselves in need of assisted living earlier in life.
❗️A doubled risk of premature death: The cumulative effects of the challenges faced, both psychological and physical, contribute to a significantly shortened life expectancy for those who are blind.

These realities underscore the importance and urgency of researching and developing innovative treatments for conditions impairing vision. The benefits of such advancements would not only restore sight but potentially address these auxiliary health concerns as well.

Don't miss us at the LSI Europe Emerging MedTech Summit 2023, taking place in Barcelona, September 18-22.

Our CEO Lloyd Diamond will be presenting the latest news from Pixium Vision, including an update on our pivotal clinical trial.

We're looking forward to connecting with everyone at the event!

Age-related macular degeneration (AMD) is estimated to affect 196 million globally. It is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. Approximately 10%–15% of all AMD patients will eventually develop the wet form of AMD. Yet, while treatments have been developed for wet AMD, those with dry AMD have fewer options.

Pixium Vision is paving the way for treatments for severe vision loss in dry AMD patients using neurostimulation technology. Pixium's innovative blend of visual processing, micro-electronics, opto-electronics, and intelligent software seeks to restore vision to retinal disease patients suffering from profound central vision impairment.

We are proud to have received FDA breakthrough device designation, and are currently concluding our one year follow up on our EU Pivotal study.